| 3,3 diindolylmethane |
NCT02197000 |
Unknown status |
Not Applicable |
A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers |
BRCA1 Gene Mutation|BRCA2 Gene Mutation |
https://ClinicalTrials.gov/show/NCT02197000 |
| 3,3 diindolylmethane |
NCT00888654 |
Completed |
Phase 2 |
Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy |
Prostate Cancer |
https://ClinicalTrials.gov/show/NCT00888654 |
| 3,3 diindolylmethane |
NCT02525159 |
Completed |
Phase 3 |
Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio |
Breast Cancer |
https://ClinicalTrials.gov/show/NCT02525159 |
| 3,3 diindolylmethane |
NCT02483624 |
Terminated |
Phase 1 |
3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus |
SLE |
https://ClinicalTrials.gov/show/NCT02483624 |
| 3,3 diindolylmethane |
NCT00784394 |
Completed |
Phase 1 |
Diindolylmethane in Preventing Cancer in Healthy Volunteers |
Healthy, no Evidence of Disease |
https://ClinicalTrials.gov/show/NCT00784394 |
| 3,3 diindolylmethane |
NCT00392652 |
Completed |
Phase 1 |
Diindolylmethane in Healthy Volunteers |
Healthy, no Evidence of Disease |
https://ClinicalTrials.gov/show/NCT00392652 |
| 3,3 diindolylmethane |
NCT01391689 |
Completed |
Not Applicable |
Diindolylmethane in Treating Patients With Breast Cancer |
Stage IA Breast Cancer|Stage IB Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer |
https://ClinicalTrials.gov/show/NCT01391689 |
| 3,3 diindolylmethane |
NCT01022333 |
Unknown status |
Phase 1 |
The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers |
Breast Cancer |
https://ClinicalTrials.gov/show/NCT01022333 |
| 3,3 diindolylmethane |
NCT00450229 |
Completed |
Phase 1 |
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer |
Adenocarcinoma of the Prostate|Prostate Cancer|Stage I Prostate Cancer|Stage II Prostate Cancer |
https://ClinicalTrials.gov/show/NCT00450229 |
| 3,3 diindolylmethane |
NCT00212381 |
Completed |
Phase 3 |
Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia |
Cervical Dysplasia |
https://ClinicalTrials.gov/show/NCT00212381 |
| 3,3 diindolylmethane |
NCT00462813 |
Completed |
Phase 3 |
Diindolylmethane in Treating Patients With Abnormal Cervical Cells |
Cervical Cancer|Precancerous Condition |
https://ClinicalTrials.gov/show/NCT00462813 |
| 3,3 diindolylmethane |
NCT00591305 |
Terminated |
Not Applicable |
New Therapy of Laryngeal Papilloma In Children |
Papilloma |
https://ClinicalTrials.gov/show/NCT00591305 |
| 3,3 diindolylmethane |
NCT03152097 |
Completed |
Not Applicable |
Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study |
Kidney Diseases|Cardiovascular Diseases |
https://ClinicalTrials.gov/show/NCT03152097 |
| 3,3 diindolylmethane |
NCT01612910 |
Withdrawn |
Phase 2 |
Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery |
Breast Cancer Female |
https://ClinicalTrials.gov/show/NCT01612910 |
| 3,3 diindolylmethane |
NCT01846364 |
Terminated |
Early Phase 1 |
DIM as a Treatment for Thyroid Disease |
Proliferative Thyroid Disease |
https://ClinicalTrials.gov/show/NCT01846364 |
| 3,3 diindolylmethane |
NCT00305747 |
Completed |
Phase 1 |
Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy |
Prostate Cancer |
https://ClinicalTrials.gov/show/NCT00305747 |
| 3,3 diindolylmethane |
NCT03802721 |
Recruiting |
Early Phase 1 |
Pharmacokinetics of Benzo[a]Pyrene: Impact of Diet |
Environmental Exposure |
https://ClinicalTrials.gov/show/NCT03802721 |
| 3,3 diindolylmethane |
NCT04292236 |
Completed |
N/A |
The Effect of Food Supplements on Food Intake and Gut Hormone Levels |
Obesity|Endocrine |
N/A |
